Pod Insights Masters of Scale Rapid Response: Riding the Ozempic wave, w/RO's CEO Zach Reitano About this episode Rabid demand for weight-loss drugs like Ozempic and Wegovy is altering US society and transforming the healthcare industry. Rapid Response host Bob Safian guides us through the upheaval and lessons, talking with CEO Zach Reitano of Ro, a telehealth platform that has ridden the wave to a $7 billion valuation. Reitano shares why he chose obesity-treatment as his company’s “hero product,” the impact of weight-loss drugs on industries beyond health-care, and why the potential of GLP-1s like Ozempic mirrors that of AI.
Read a transcript of this episode: https://mastersofscale.com https://mastersofscale.com/
Subscribe to the Masters of Scale weekly newsletter: https://mastersofscale.com/subscribe
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Transcript 0:01 Speaker 00 We've all spent money on something that seemed incredible but didn't live up to the hype. A kitchen gadget, a car. When it doesn't deliver, the disappointment is real. Marketers suffer from this too. Chasing metrics that look great but don't translate into revenue. LinkedIn calls that bull spend. Invest in what matters and reach the right buyers with LinkedIn Ads. You can target by company, industry, job title, and more. LinkedIn Ads also generates the highest ROAS of all major ad networks. Spend $250 on your first campaign on LinkedIn Ads and get a $250 credit for the next one. Just go to LinkedIn.com/scale. That's LinkedIn.com/scale. Terms and conditions apply.
0:48 Speaker 00 The very best founders I know are brilliant at building systems. They connect teams, they remove bottlenecks, and they eliminate single points of failure. And yet, when it comes to their own wealth, most are running a disconnected stack. A tax accountant here and a state attorney there, a wealth manager who doesn't talk to either one of them. Creative Planning was built to fix exactly that. One integrated team of tax professionals, state planners, investment specialists, all coordinated by a dedicated wealth manager who sees your full financial picture and keeps every piece working together. Proactive tax efficiency,
1:29 Speaker 00 estate strategy, investments, all under one roof. Creative Planning, where wealth works together. Learn more at creativeplanning.com/mastersofscale.
1:41 Speaker 01 AI is full of possibilities. Enterprises run on realities. That's why Pega combines the world's most powerful AI with the governance, transparency, and control enterprises demand. So you can move faster, adapt faster, and scale AI with confidence. All the power of AI, none of the uncertainty. Learn more at Pega.com/AI.
2:08 Speaker 02 It is reported that over nine million people living in the U.S. are on weight loss drugs.
2:14 Speaker 03 It's the talk of TikTok. Ozempic is a drug you inject that's meant to improve blood sugar and help manage type 2 diabetes. But because one of the side effects is weight loss, many are using it off-label, a trend that may have started in Hollywood.
2:34 Speaker 04 A drug shortage is impacting people living with diabetes, and some pharmacies say they just can't get it in stock.
2:40 Speaker 05 We are just getting started. Millions of people are going to have seen the benefits. Well, then, people are going to want to talk about what's the cascading impact on society. Look at the impact it's had on the grocery business or the restaurant business or travel or the healthcare system, you name it. You know, only a few million people have this, but 110-plus million people are eligible. There's a long way to go before we're done talking about this.
3:09 Speaker 06 Bob Safian here. The boom in weight loss drugs like Ozempic and Wegovy is rippling across society and the business world. Today, I'm talking with Zach Reitano, CEO of telehealth platform Ro, which has ridden the weight loss craze to a $7 billion valuation. It's been fueled by a series of rapid responses. Reitano likens the tumult around weight loss drugs to the furor around AI, that the cascading impacts in terms of health, economics, and culture will be more far-reaching than we can imagine. This is Rapid Response.
3:57 Speaker 06 I'm Bob Safian. I'm here with Zach Reitano. Founder and CEO of telehealth company Ro. It's good to see you, Zach.
4:05 Speaker 05 It's good to see you, Bob. Thanks for having me.
4:07 Speaker 06 So in the last year, the appetite for weight loss drugs like Ozempic and Wegovy and other so-called GLP-1s has just exploded. Patients, doctors, healthcare companies, all scrambling. Denmark's Novo Nordisk, maker of Ozempic and Wegovy, is so on fire. It's now responsible for most of that country's growth. Kind of amazing. Your business, Ro, has been part of this whirlwind.
4:34 Speaker 05 Yeah, absolutely. I'll first start, actually, I think, by giving a little bit of context. GLP-1s satisfy, at Ro, what we think is they satisfy five criteria never before seen in medicine. And the combination of those five things has created this unprecedented demand. The first is that the majority of the US population is eligible for the drug. Right? So that we've really never had before, other than maybe vaccines at times. But 75% of the US population has overweight or has obesity, and probably about 60% are eligible for the treatment. The second is it's incredibly effective, two, three, sometimes four times more effective than existing solutions, right? Surgical interventions are comparable.
5:18 Speaker 05 But the third point is that far less scalable. So you have the majority of the US population eligible, extremely effective, quite scalable. The fourth is that patients want it. And the fifth is that providers and the majority of the healthcare system over time want patients to have access to it, right? So those five things create this unprecedented demand.
5:39 Speaker 06 You started your company focused on erectile dysfunction, but early last year, you launched what you called the Body Program, focused on obesity. And that timing, I mean, it couldn't have been better.
5:51 Speaker 05 In those instances, when the timing comes together in sort of these weird ways, sometimes it's better to be lucky than good, right? Like erectile dysfunction just happened to be a side effect of my heart medication. And I happened to get re-prescribed that medication at the very same time that there was a large transition of branded drugs to generic drugs that these patents were expiring, at the same time that telemedicine laws were being updated. So there were so many things related to timing circumstances where we just got lucky.
6:22 Speaker 06 And with the new obesity program, your timing there was just as a wave of demand came rolling in.
6:28 Speaker 05 We launched the Robodi membership, as you alluded to, in January 2023. And by May, there was a national shortage of Vugovi, which for a drug that needs to be taken weekly, that is titrated up, which means that patients start at a low dose. As their body gets used to it, they might hit what is referred to as maintenance or a steady dose, and that varies based on patients. But patients take a once-weekly injection, and they need to do it on a continuous basis. And so when there's a national shortage and patients are getting different doses over time, it becomes harder and harder for them to hit that next dose. And so what we did in May, we went from advertising a significant amount.
7:13 Speaker 05 We took over Grand Central, we took over subway stations, we were advertising on TV, Facebook, Google, you name it, all of the different channels that I'm sure people on the pod are very familiar with, we stopped advertising.
7:25 Speaker 06 You stopped because you had too many people already coming in?
7:29 Speaker 05 We stopped because we saw that the people that were on the platform and that were currently coming in as well, we needed to devote all of our energy to making sure that they were able to get medication on a continuous basis. And we didn't want to exacerbate that problem by fueling demand with advertising.
7:48 Speaker 05 So we stopped advertising. We issued credits to all of our members that were unable to pick up medication within 30 days. So a lot, a lot, a lot of refunds and credits. We shifted all of our existing resources to finding supply at different pharmacies. So in July and August alone of 2023, our, our team made well over 40,000 to 50,000 phone calls to different pharmacies throughout the country.
8:16 Speaker 06 Phone calls, like, are you literally like on a phone yourself manually?
8:20 Speaker 05 A hundred percent.
8:21 Speaker 06 Wow.
8:22 Speaker 05 So if we're able to find stock at a pharmacy, we immediately could see what other patients in that zip code or within a specific number of miles, five, 10, 15, 30 miles, ping those patients, say we found supply. It's here. Can you go get it? And then we would go, go back to the pharmacy, reserve it or transfer a prescription to that pharmacy. So there's, it was a sort of a massive game of whack a mole there to try and find supply for patients. And then we added drugs to the formulary. One of them was Sixenda. It's a daily injection. It's, it's, it is less effective, but it's still more effective than alternative options. That then went on shortage.
9:02 Speaker 05 And then at the end of November, early December, Lilly launched a, or launched a drug called Zepbound. And that allowed us to start advertising again, start onboarding patients because we had extremely high confidence as we added that to the formulary that they would be able to access some form of, of treatment.
9:21 Speaker 06 To put yourself in this position required a series of responses that you guys went through, starting back in 2021. And the, the company had provided obesity treatments before, but in the summer of 2021, you kind of had an epiphany.
9:39 Speaker 05 My dad, who's a physician, and he's actually, and I can share this part with a big smile on my face, but he has saved my life. He saved my sister's life. He saved my mom's life. Cause we've all at one point in time or another had life threatening illnesses. I have a congenital heart condition and he helped me navigate that. But even as a physician himself, he has always struggled with his weight for as long as I can remember, my entire life. And I saw the fights that that created because when people don't understand the cause of obesity, they make the false assumption that it's willpower, that it's self-discipline. And so you see this person in my dad, who's devoted his life to his family, devoted his life to helping others, but why can't he just do this one thing for us?
10:22 Speaker 05 Why can't he just lose weight and get healthy and be there for us as we want him to be? And again, it's out of love and fear, but it was driven by what a lot of people have, which is a misperception of obesity as a disease. And so my dad was seeing an obesity specialist and he ended up being prescribed his Epic and now he's on Munjaro, actually. And he lost 40, 50 pounds. I saw him in almost a matter of like a week or two, go from this drive, this obsession, as he would describe it, with food, and it disappeared almost overnight.
11:04 Speaker 05 His midnight trips to the kitchen, all of them disappeared. When I heard that, him articulate that, and then look at the number of people that we were helping, the number of people that were asking for it, and saw that there was an opportunity to replicate that experience for millions of people, and knew that was the most profound thing I thought that we could do and build at the time.
11:31 Speaker 06 So you went down the rabbit hole, as you've described it, studying obesity drugs and the weight loss landscape. And when you climbed out of that hole, you decided to shift the whole company in this direction, which was a risky bet.
11:45 Speaker 05 We made a uncomfortably large investment there, probably ahead of where people thought maybe it warranted at the time. And ahead of, not only because it was such a large investment relative to our business and our resources at the time, but also because people had doubts. Weight loss is a category from a clinical perspective that is littered with failures and with over-promising, under-deliver. And then not to mention, this was a... Weekly injection. So there were so many reasons why people thought this will never, this is never going to work.
12:20 Speaker 06 Those doubts included doubts inside your own organization, right? There were, there were folks in the company who weren't quite sure this was where the company should go.
12:29 Speaker 05 Yes, that is, that is true. To me, it was, it was, I was like, gonna be obvious that I thought the world would be so impacted by these things. Sometimes you're right, sometimes you're wrong, but it takes a tremendous amount of trust by the team. So the team, I think, said, you know, classic disagree and commit. And then, once they saw, and it didn't take much, I think it didn't take much convincing, once people saw the impact that it had on patients' lives.
12:55 Speaker 06 You said to me, when we talked earlier, that we needed a hero product to build the brand. It sounds almost like you were looking for something at the same time that this appeared to you.
13:06 Speaker 05 Building a brand is part art, part science, and, uh, cause if it was just pure science, everyone, everyone would be able to do it. I, I deeply believe that you need a single hero product to build a brand. It's the initial tip of the spear. It's how people are introduced to the company and to the, to the promise that you're making to them. And over time, I think when people talk about, oh, you know, your brand will only be known for one thing, that's a champagne problem. That means you found product market fit, which is the hardest thing to do as a, as a company or as a product when you're first starting.
13:40 Speaker 06 And you first started, the product was ED related, right? That was your hero product in the beginning that you were known for.
13:48 Speaker 05 Yeah. So we, we first launched the company under the name, under the brand Roman. And the first product was erectile dysfunction. We always knew that we wanted to treat patients of all ages, sexes, genders, across the country. And so we knew that, even as we were building the brand, we knew that Roman wasn't going to be the, the end state. But we sort of wandered our way to try and find the right solution. We tried a house of brands. We had Roman, we had Rory for women's health. We had Zero for smoking cessation. We had Rhoderm for dermatology. We had a bunch of different brands. And ultimately, the thing that I think we realized is we wanted one brand that represented the ethos of the company.
14:32 Speaker 05 And so we put all of our products and services under one brand. But to your point, we still needed a hero product. How would the majority of people learn about Rhod? We had a strong hypothesis that obesity would be that would be that hero product.
14:47 Speaker 06 So you made the call to lean into obesity as your hero product. You made what you call an uncomfortably large investment. But as you're building that out, you also realize you need to restructure the company.
15:01 Speaker 05 Building a company is a continuously humbling experience. You're constantly doing things where you're wrong. It's this weird combination of when you're building a company, you need to have such conviction in what you're doing because there's so many hurdles and so many people are telling you no all the time. They're telling you your idea is stupid. We were laughed out of the room when raising money constantly. We, you know, when we raised our Series A, there were 40 noes out of 43 pitch interviews and pitches. So it's this really difficult tension between needing to have really high conviction and being wrong a lot and being told no all the time. And in 2022, my co-founders and I refounded the company.
15:44 Speaker 05 And that included some of the things we've mentioned thus far. It included bringing everything under one brand. So that was part of the refounding. The second thing we did is we moved on from just about 20% of the company. That's some humble pie, too, when you have to move on from people because in large part it was our doing. You know, ultimately, founders and CEOs are accountable. And whenever you have to do a layoff, it's fully on you, right? And so that is, that's a big mistake that we will, we will have to live with and learn from. And the next thing actually that we did was we shut down. A few of our products, revenue generating products that we shut down, but to narrow our focus even more.
16:24 Speaker 05 The confluence of those four things has worked together to create the re-acceleration that Ro has seen.
16:32 Speaker 06 You've called these drugs the healthcare equivalent of AI. Explain why GLP-1s are like AI.
16:39 Speaker 05 In the same way that AI is this unbelievable, let's say facilitator of leverage for society. I think that what we are seeing is that these drugs are going to have a profound impact. We're going to see a tremendous impact on the healthcare system from the surgeries that are needed, to the procedures that exist, to the level of, down to like the number of auto-injectors that are built and developed. People eat 30% fewer calories. What they eat changes. They eat far less ice cream, far more fish, poultry, vegetables, and then lifestyle behaviors. On the other side of people losing weight, do they exercise more or less? Marriage and dating, you actually see an increase in both marriages and divorces
17:24 Speaker 05 on the other side of large impacts of body composition. And so, we can't yet fathom, predict, digest the true cascading impact of AI. And I definitely think we can't truly understand the cascading impact of GLP-1s 5, 10, 15, 20, 30, 50 years from now.
17:40 Speaker 06 Cascading impact akin to AI. I hadn't thought about weight loss that way, but I guess if obesity truly becomes a thing of the past, who knows what the impacts might be? After the break, we'll dig into why Zach believes the stigma around obesity is an opportunity and more. We'll be right back.
18:01 Speaker 00 We all know the disappointment that comes when a grand gesture falls flat. Something that seemed impressive in the moment, but didn't deliver the results you expected. Marketing budgets too often fall into that trap, aiming for big impressions, big reach, but without the revenue to back it. LinkedIn has a name for it, Bull Spend. LinkedIn Ads generate the highest ROAS of all major ad networks. They target by company, industry, job title, and more. Spend $250 on your first campaign on LinkedIn Ads and get a $250 credit for the next one. Just go to LinkedIn.com/scale. That's LinkedIn.com/scale. Terms and conditions apply.
18:44 Speaker 00 When you've built substantial wealth through your business, it's often tied up in a single equity position. The upside is real, but so is the risk, and knowing when to act isn't always obvious. Creative Planning works with business owners to build a strategy around concentrated equity, when to diversify, how to manage tax risk, and how to protect what you've spent years building. Creative Planning, where wealth works together. Learn more at creativeplanning.com/mastersofscale. Stripe Treasury is your new financial operating system built for what's next. With Stripe Treasury, the place your business accepts payments is also where you can store balances, move funds, and pay vendors worldwide.
19:29 Speaker 00 If you're building for global scale, get a business bank account that lets your money move instantly, whenever and wherever you need it. Learn more at stripe.com/treasury. Stripe is not a bank. Banking services provided by Fifth Third Bank, National Association Member, FDIC.
19:47 Speaker 06 Before the break, we heard CEO Zach Raitano of Ro talk about the storm around weight loss drugs Wegovy and Ozempic. Now, we talk about the stigma attached to obesity and the risks and opportunities he sees in that. Plus, Zach gives more detail on the drug's cascading impact for businesses beyond healthcare. Let's jump back in.
20:10 Speaker 06 Fueled by TikTok videos and celebrity testimonials, like, people are seeking out weight loss prescriptions who may not be obese for other reasons, for image of a body image or other things. What's your responsibility in addressing that phenomenon?
20:29 Speaker 05 We only facilitate treatment and high-quality obesity care for patients who have obesity and are considered "on-label" for the drug, which means they either have a BMI of 27 to 30 with a comorbidity, or they have a BMI of 30-plus. Now, knowing also that BMI is because that is the label, that is what is required by the FDA on the label, we could talk for hours about the flaws of BMI and why it is used, but I will just say, Ro treats patients that are on label for the drug, and we have a rigorous qualification process in order to make sure that we are only doing that. I think that the reason we're all talking about this so much is because there is so
21:11 Speaker 05 much stigma attached to obesity and to weight loss and to the way that it's achieved. And it's tough, right? Because there's so much here. Obesity is, it's attached to so many different components. There's sustainability, there's lifestyle choices, what we eat, what we feed our kids, how we gather, how we celebrate. There's so much that food consumption and exercise and health are wrapped up into, that we all have very strong feelings towards it. And that does impact how society judges it, and how likely someone is to receive treatment, and how people who seek treatment are viewed. And so hopefully, we can break down a lot of that stigma together.
21:51 Speaker 06 Yeah, you've been, from the beginning, with Ro and First. Now, Ro, you've been focused on often areas where there are stigma or shame, erectile dysfunction, baldness, obesity. It's interesting, because in those areas, like sometimes, yeah, customers want to be seen and validated, and normalized, which I think is what you're doing. But at the same time, these are personal areas that sometimes users might not be comfortable with. And you've relied on a lot of, like, you mentioned marketing earlier, but a lot of real eye-catching marketing efforts all the way through this journey. Is there a philosophy around that relative to this issue of shame and stigma?
22:28 Speaker 05 Yes. Again, it comes back to unapologetic, patient-centricity. So I'll take our Out of Home campaign for obesity and for the body program. And we showed patients that were of an eligible BMI in the ads, which is not always done by companies in the space, but that is done by us. And we showed these patients at positions of power, and positions where they had tremendous agency, real strong power poses. And then we showed them using the medication. And the only thing we described was we said a weekly shot to lose weight. And this caused outrage.
23:11 Speaker 05 And the the source of the outrage is very understandable. It's because body composition, body shame has existed for far too long and it's too strong a force in our society. And no one should feel shame about their body and when they wake up. They should, you know, loving yourself is very, very important. And even even the words body positivity, a lot of it is right now, the community is trying to shift and evolve to body neutrality, to trying to reduce the role that your physical appearance plays in your emotional and mental health. So what was fascinating is that people did have this philosophical hurdle around someone seeking medical treatment for obesity.
23:53 Speaker 05 And a lot of it is because of the stigma that is attached to it. The fact that people do see it as a as a flaw of self-discipline and willpower. And so what we but but the individuals who are impacted by it, I can tell you that advertisement resonated with them. For us, the advertisements that we create, we say, what will resonate with the people who need this treatment or access to this? We solely focus on that. And if that frustrates other people, so be it, because we are speaking to the people who want and need our help. And that, I think, is, again, it's about being unapologetically patient centric. And that's sort of the guiding principle for us, right? And even erectile dysfunction or sex, people have sex. It's how the vast majority of us are here. Yeah, we don't want to talk about it.
24:38 Speaker 05 We don't want to talk about the role that it plays. We don't want to talk about the fact that someone having positive consensual intimacy with their partner more frequently than not is a good thing for themselves, their life. There's no shortage of research that shows that healthy sexual relationships has a positive cascading impact on people's lives. And then if you're unable to, that's a problem for those people for whom it impacts. They deserve to have it fixed in a discreet, fast, affordable, effective, seamless way.
25:06 Speaker 06 Ozempic can cost, you know, almost $900 a month right now for for a supply. What is the future of that? Because it seems. That's a, that's a big bird for a lot of people to carry indefinitely.
25:20 Speaker 05 Right now, there's people who have insurance coverage and people who have to pay cash. If you're not covered, you might pay around $550 a month. So the people, let's just say broadly, right now, the people who are not covered pay $550 a month on average. That's still too expensive. For the people who are covered, there are tens of millions of people who are covered. So about 30 to 40% of employers cover it. That's about 50 million people. When they are covered, the publicly available data says that when someone's covered, 80% of the time, they pay $25 or less. And we do see the vast majority of patients on our platform pay less than $100 a month when they're covered. So about 30, 40% of commercial plans cover it. All federal employees cover it. So I think that's an amazing, or are covered, them and their families.
26:05 Speaker 05 I think that's an amazing step by the US government. Over time, what you will see is as more and more pharma companies enter, or as there's more and more competition, we'll hopefully see prices come down. The, in addition to prices come down, there's research being done that highlights the benefits beyond obesity. So in addition to society catching up to the underlying health impact of, of excess weight and excess adipose tissue, the label will expand to cover more things. Heart disease, chronic kidney disease, sleep apnea, as I mentioned before, it's being studied for all these things. And what you're also seeing is you're seeing the pipeline here is tremendous, where it's going from once a week injectables to some that are being studied for once a month, some that are being studied once every six months,
26:50 Speaker 05 some that are being studied really early on for almost vaccine-like, once a year. That's far less expensive, right? 52 times a year versus once. And then you're seeing oral versions of GLP-1. So daily tablets, twice a day tablets being studied. Tablets are far easier to scale than, than these injectables. So there's a lot that's happening that will hopefully drive down the price, increase access, and make it sustainable for people to maintain use.
27:16 Speaker 06 The last year's focus on these drugs, some would say hype.
27:22 Speaker 06 Will it continue? Will people keep talking about these same drugs the same way when there isn't a demand shortage? And is that good or bad? Like, how do you think about sort of keeping the momentum going?
27:34 Speaker 05 I think that we are just getting started. And there's a few reasons why that's the case. One actually is the shortage. So right now, the things that people want to talk about, things that we talked about last year, things that impacted us was the shortage. But, and that because of the demand and sort of the quote unquote out of stock, like that's topic, that's discussion worthy. But what are we going to see? What are we going to talk about in 24 or 25 is when it, when it ends, right? Millions of people are going to have seen the benefits. Well, then people are going to want to talk about, well, what are the, what are the, what's the cascading impact on society? Look at the impact that it's had on people's health. Look at the impact it's had on the grocery business or the restaurant business or travel or the healthcare system, you name it, the sort of cascading impact.
28:14 Speaker 05 So I think because we're just getting started with access in the first place and our understanding. So, you know, only a few million people have this, but 110 plus million people are eligible. There's a long way to go before we're done talking about this. Because it really is, and the pipeline is tremendous as well. So it's not just Bogovi or Ozempic or Zepbound, Munjaro and Saxenda, but over the next three, five, 10 years, you're going to see this, we're, we're in the middle of this Cambrian explosion of our understanding of, of cardiometabolic health, which will lead to all of these different inventions. So I think that you will see the, not only this drug and this drug class, but what this
28:57 Speaker 05 drug class spawns and in terms of understanding our overall health.
29:03 Speaker 06 Zach, thanks for jamming with us. I do appreciate it.
29:06 Speaker 05 I appreciate the time and thanks for the great questions, Bob.
29:09 Speaker 06 I'll confess that the craze around weight loss drugs took me by surprise. Maybe it shouldn't have, but I'm still kind of amazed that Zach saw it coming years ago. What strikes me most is how progress can emerge in unexpected ways and unexpected areas.
29:25 Speaker 06 When I first heard about these treatments, I viewed it as just another fad in the vanity-driven quest for thinness. But as Zach describes it, it has the potential to mitigate some of the biggest drivers of disease, improving lifespans and health spans, and unleashing a slew of other opportunities. Of course, that potential isn't just about science. Businesses like Ro and others play a critical role, ensuring that these treatments are used responsibly and that they aren't just made available to the rich. We'll keep watching and learning. I'm Bob Safian. Thanks for listening.
30:01 Speaker 00 Global hiring is such a headache when you're building fast, but don't let payroll, compliance, or onboarding slow you down. Companies like Eleven Labs and Mistral are scaling globally and effortlessly with Deal. Eleven Labs quadrupled their headcount in 2025, and Mistral pays 364 employees across 15 countries, all from one system. Build your global team with Deal. Visit deal.com/mos and start expanding your business today. That's D-E-E-L dot com slash M-O-S.
30:37 Speaker 00 Before we get to the rest of our conversation today, I want to spend a moment sharing with you about Masters of Scale Summit, which returns to San Francisco this October 20th to 22nd. So many of us feel overwhelmed right now. It feels like so much of the world is careening, and we don't have power. We don't have agency. That's the thing about the Masters of Scale Summit. It's really designed to remind us that we do have agency. Agency to lead, agency to design, to build the relationships and the partnerships that empower us and to make the change that we want to see. We program a stage, we curate an audience, we set a schedule that builds in time for these relationships to be made and to grow, so that by the time you leave summit, you
31:22 Speaker 00 are fired out of a cannon, ready to run through walls to do better in the world with the agency that you actually have. I hope to see you there. Visit mastersofscale.com/summit.
31:40 Speaker 00 Every business hits the same wall the moment your business outgrows the systems that got you here. Spreadsheets everywhere, five different logins, data scattered across entities that don't even talk to each other. If your finance team spends more time finding data than using it, that's when you need the Intuit ERP. Intuit Enterprise Suite is the AI-native ERP solution that's powerful, painless, and proven, built for businesses scaling fast without the complexity that usually comes with it. From the makers of QuickBooks, learn more at intuit.com/erp.
32:21 Speaker 06 Rapid Response is a Wait What original. I'm Bob Safian. Our executive producer is Eve Tro. The production team includes Chris Gautier, Alex Morris, Masha Makutoneena, and Brandon Klein. Audio editing by Keith J. Nelson, Stephen Davies, Stephen Wells, and Andrew Nault. Mixing and mastering by Aaron Bastinelli. Original music by Eduardo Rivera and Ryan Holiday. Our head of podcasts is Lital Malad. Visit mastersofscale.com to find the transcript for this episode and to subscribe to our email newsletter.
33:07 Speaker 06 Hey, listeners, Bob here. If you listen to Rapid Response on Masters of Scale, you may be missing half the show because every Friday we release a second Rapid Response exclusively in the Rapid Response feed. The guests and topics are just as compelling and timely, from Ford CEO to NASA's administrator to the lessons from the devil wears Prada. It takes about 10 seconds to find. Just search Rapid Response wherever you listen to podcasts and hit follow to make sure you never miss an episode. I hope to see you there.
Previous Leading across great divides: Ian Bassin, Protect Democracy Executive Director Next How to score $200M: Angel City’s playbook for women’s soccer Page updated October 26, 2026 · transcript and summary are machine-generated